These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8889080)

  • 61. Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments, and prospects.
    Young JL; Spitz RT; Hillbrand M; Daneri G
    J Am Acad Psychiatry Law; 1999; 27(3):426-44. PubMed ID: 10509942
    [TBL] [Abstract][Full Text] [Related]  

  • 62. From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication.
    Gray R; Wykes T; Gournay K
    J Psychiatr Ment Health Nurs; 2002 Jun; 9(3):277-84. PubMed ID: 12060371
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [CUtLASS 1 - Increasing disillusion about 2nd generation neuroleptics].
    Steinert T
    Psychiatr Prax; 2007 Jul; 34(5):255-7. PubMed ID: 17607643
    [No Abstract]   [Full Text] [Related]  

  • 64. Schizophrenic patients' experiences of neuroleptic medication: a Q-methodological investigation.
    Day JC; Bentall RP; Warner S
    Acta Psychiatr Scand; 1996 May; 93(5):397-402. PubMed ID: 8792911
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP].
    Buis C; Gourion D; Vaiva G
    Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185
    [No Abstract]   [Full Text] [Related]  

  • 66. [Can psycho-education of chronic schizophrenic patients have a short-term effect on drug-related attitude and behavior?].
    Hornung WP; Franzen U; Lemke R; Wiesemann C; Buchkremer G
    Psychiatr Prax; 1993 Jul; 20(4):152-4. PubMed ID: 8103230
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Medication compliance and substance abuse among schizophrenic patients.
    Pristach CA; Smith CM
    Hosp Community Psychiatry; 1990 Dec; 41(12):1345-8. PubMed ID: 1980483
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Issues in drug administration in a psychiatric rehabilitation unit.
    Trauer T; Vaddadi K; Soosai E
    Int J Soc Psychiatry; 1995; 41(3):174-9. PubMed ID: 8847198
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The problem of drug compliance in schizophrenic patients].
    Albus M
    Psychiatr Prax; 1995 Nov; 22(6):221-2. PubMed ID: 8570750
    [No Abstract]   [Full Text] [Related]  

  • 70. The meaning of antipsychotic medication to patients with schizophrenia.
    Seeman MV; Seeman N
    J Psychiatr Pract; 2012 Sep; 18(5):338-48. PubMed ID: 22995961
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Compliance in therapy of schizophrenic patients with neuroleptics--an overview].
    Mayer C; Soyka M
    Fortschr Neurol Psychiatr; 1992 Jun; 60(6):217-22. PubMed ID: 1353747
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A virtual reality apartment as a measure of medication management skills in patients with schizophrenia: a pilot study.
    Kurtz MM; Baker E; Pearlson GD; Astur RS
    Schizophr Bull; 2007 Sep; 33(5):1162-70. PubMed ID: 16956984
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
    Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
    Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years.
    Linden M; Godemann F; Gaebel W; Köpke W; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
    Schizophr Bull; 2001; 27(4):585-96. PubMed ID: 11824485
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
    Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
    Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia.
    Patel MX; Nikolaou V; David AS
    Psychol Med; 2003 Jan; 33(1):83-9. PubMed ID: 12537039
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost of relapse in schizophrenia.
    Weiden PJ; Olfson M
    Schizophr Bull; 1995; 21(3):419-29. PubMed ID: 7481573
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Indicators of medication compliance in first-episode psychosis.
    Kampman O; Laippala P; Väänänen J; Koivisto E; Kiviniemi P; Kilkku N; Lehtinen K
    Psychiatry Res; 2002 May; 110(1):39-48. PubMed ID: 12007592
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication.
    Rettenbacher MA; Hofer A; Eder U; Hummer M; Kemmler G; Weiss EM; Fleischhacker WW
    J Clin Psychiatry; 2004 Sep; 65(9):1211-8. PubMed ID: 15367047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.